Journal
BREAST CANCER RESEARCH
Volume 13, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/bcr2791
Keywords
-
Categories
Funding
- Pamela Greenaway Kohlmeier Translational Breast Cancer Research Unit
- London Regional Cancer Program
- Canada Research Chairs Program
Ask authors/readers for more resources
Breast cancer is a heterogeneous disease. Patient outcome varies significantly, depending on prognostic features of patients and their tumors, including patient age, menopausal status, tumor size and histology, nodal status, and so on. Response to treatment also depends on a series of predictive factors, such as hormone receptor and HER2 status. Current treatment guidelines use these features to determine treatment. However, these guidelines are imperfect, and do not always predict response to treatment or survival. Evolving technologies are permitting increasingly large amounts of molecular data to be obtained from tumors, which may enable more personalized treatment decisions to be made. The challenge is to learn what information leads to improved prognostic accuracy and treatment outcome for individual patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available